Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study is expected to demonstrate the anti-diabetic efficacy of 3-months treatment with
GFT505 (80 mg/d) on Glycosylated Haemoglobin A1c (HbA1C) and fasting plasma glucose.
And to assess the tolerability and safety of once-a-day administrations of oral doses of
GFT505 for 12 weeks in patients with type 2 diabetes mellitus.